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Abstract: The dawn of the biologic era has been an exciting period for clinical research and 
patient care in rheumatoid arthritis (RA). Targeted biologic therapies have changed the  outcome 
of this disease and made remission a realistic outcome for many patients. Tocilizumab (TCZ, 
Actemra®), is a humanized monoclonal antibody against the interleukin 6 receptor and has 
been approved in many countries for the treatment of moderate to severe RA. There have been 
a number of important clinical trials demonstrating the efficacy of TCZ in active rheumatoid 
arthritis. This review summarizes the data on efficacy, patient-reported outcomes, adverse 
events, and safety from some of these trials. Current trends in clinical practice will be discussed. 
It is difficult to place TCZ and many new medications in the algorithm of treatment at  present. 
 However, the next few years will hopefully reveal their role as we better define abnormal 
immune processes in individuals with RA.
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Introduction
Rheumatoid arthritis (RA) is a chronic systemic disease, with complex genetic 
and environmental factors acting together to cause inflammation and damage. This 
 primarily occurs in the synovium and joint tissues, with typical clinical features being 
 swollen painful joints and stiffness. Important extra-articular features include lung and 
cardiovascular disease. There is other organ involvement, and manifestations include 
anemia, fatigue, skin nodules, neuropathy, ocular disease, splenomegaly, vasculitis, and 
pleuropericarditis.1,2 There is a prevalence range of 0.5%–1.0% in many populations, 
with women being affected up to three times as often as men. The annual incidence 
of RA has been shown to be about 30 per 100,000. Peak onset of the disease is at 
30–55 years, but it can occur at any age.2,3
To prevent joint damage, disability, economic loss, and mortality, clinicians prefer 
aggressive therapy, with a common goal of remission. Despite the widespread use of 
disease-modifying antirheumatic drugs (DMARDs) and biologic agents in various 
combinations, some patients still have persistently active disease. Although there are 
various guidelines for treatment,4–6 each patient is managed individually, based on 
disease activity, prognostic signs, and functional impairment. There is a strong recom-
mendation to use a biologic agent only after failure of nonbiologic DMARDs, unless 
high disease activity is present with poor prognostic signs.5,6 There are no consensus 
guidelines on which biologic agents to use after failure of a DMARD. However, there 
are trends in practice that are influenced by previous experience, tolerability, drug 
availability, and cost or insurance issues.
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Interleukin (IL)-6 is a pleiotropic proinflammatory 
cytokine that is produced by multiple cell types, but of 
importance in RA, it induces osteoclast differentiation and 
can be responsible for joint destruction. Increased serum and 
synovial fluid levels of IL-6 are correlated with RA disease 
activity.7,8
DMARDS available
Methotrexate (MTX) is the dominant small-molecule or 
nonbiologic DMARD,9 and is usually used as monotherapy 
or in combination with other DMARDs as a first-line agent in 
RA. There are guidelines in the UK4 that support  combination 
DMARDs (MTX and at least one other DMARD) as first-
line therapy; however, others feel that there is no significant 
advantage to this approach.10,11 DMARDS that are used alone 
or as combination therapy with or without MTX include 
leflunomide, sulfasalazine, and hydroxychloroquine. Gold 
agents, azathioprine, and cyclosporine are rarely used 
 anymore. Nonsteroidal anti-inflammatory medications, 
as well as corticosteroids, are used in conjunction with 
DMARDs. Low-dose long-term corticosteroids are effec-
tive in some patients.12,13 Individuals with persistently active 
disease after a single DMARD or a combination of DMARDs 
are given a biologic agent. Some individuals with moderate 
to severe disease are given a combination of DMARD (such 
as MTX) plus a biologic agent as first-line therapy. MTX 
as monotherapy or in combination with small-molecule 
DMARDs has been shown to be effective as initial treat-
ment, demonstrating a good outcome without the need for 
biologic therapy in some patients.14–16 The cost-effectiveness 
of  biologics as first-line therapy is not as high as for conven-
tional DMARDs as first-line therapy.17
In addition to the DMARDs discussed above, there are 
nine biologic therapies approved for RA in the US18 and 
Europe.19 Etanercept is an IgG fusion protein produced 
through the recombinant soluble p75 receptor for tumor 
necrosis factor-alpha (TNF-α). Infliximab is a mouse-human 
monoclonal antibody against TNF-α. Adalimumab is a fully 
human TNF-α monoclonal antibody. Many trials have shown 
the effectiveness of these three biologics that were the first to 
be approved for RA.14,15,20–26 When one of these agents fails 
or has to be discontinued, the choice of second-line biologic 
is up to the clinician, because it has been seen that efficacy 
varies on an individual basis.27 Data show that there is a high 
rate of continuation of the second agent when switching from 
one TNF-α inhibitor to another.28,29
There are newer therapies available that are used after 
the initial biologic fails due to persistently active disease, 
or at times these may even be used as the initial biologic. 
Certolizumab pegol, a PEGylated Fab’ fragment on a 
 humanized monoclonal TNF-α inhibitor antibody, was 
recently approved and is effective in moderate to severe 
RA.30–32 Golimumab, a fully human monoclonal antibody 
against TNF-α, can be administered monthly.33 Abatacept, 
a fusion protein (cytotoxic T lymphocyte-associated anti-
gen 4 fused to immunoglobulin) inhibits the costimulation of 
T cells successfully in patients refractory to DMARDs and 
other biologics.34–36 Rituximab, a monoclonal antibody to 
CD20, depletes B lymphocytes and is used in a variety of 
inflammatory disorders, including RA.37 Anakinra is an IL-1 
antagonist approved for RA and is given as a daily injection, 
so is less convenient and has a higher risk of injection site 
reactions than the TNF-α inhibitors.38,39
Despite the currently available therapies, there are patients 
who do not respond to DMARDs and biologics, or encounter 
problems with adverse effects and tolerance. For this reason, 
there is a continued demand for new therapies. Some that are 
currently in development and at the trial stages are agents 
targeting IL-1, cytokines from the TNF  superfamily, IL-15, 
IL-17, B lymphocytes, IL-12/IL-23, SyK kinase, JAK3 
kinase, and inhibitors of osteoclastogenesis.40–51
Chemistry and mechanism of action
Tocilizumab (TCZ) has a molecular weight of about 148 kDa 
and is a recombinant humanized antihuman IL-6 receptor 
monoclonal antibody of the IgG1κ subclass with a typical 
H
2
 L
2
 polypeptide structure. The four polypeptide chains are 
linked intra- and intermolecularly by disulfide bonds; heavy 
chains consist of 448 amino acids and light chains consist 
of 214 amino acids.52
IL-6 is a pleiotropic proinflammatory cytokine produced 
by synovial and endothelial cells, so is produced in areas 
affected by inflammation. It is produced by T cells, B cells, 
lymphocytes, monocytes, and fibroblasts, and has a role 
in T cell activation and immunoglobulin secretion. IL-6 
is involved in hepatic acute-phase protein synthesis and 
stimulation of hematopoietic precursor cell proliferation 
and differentiation. IL-6 signal transduction is mediated by 
membrane-bound and soluble IL-6 receptors. TCZ binds 
to both of these receptors and inhibits signaling via this 
route.52,53
Pharmacodynamics
Studies of TCZ 4 mg/kg and 8 mg/kg have shown increased 
rheumatoid factor, erythrocyte sedimentation rate, C-reactive 
protein, and serum amyloid A, as well as increased 
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hemoglobin. Greater changes were observed with 8 mg/kg. 
Healthy individuals given TCZ (2–28 mg/kg) showed a 
decrease in absolute neutrophil counts (nadir 3–5 days). RA 
patients followed a similar pattern.52
Pharmacokinetics and metabolism
A population analysis of 1793 RA patients treated with 
TCZ (4 mg/kg and 8 mg/kg every four weeks for 24 weeks) 
was used to determine pharmacokinetics, which are similar 
between healthy individuals and RA patients. Age, gender, 
and race did not affect the pharmacokinetics of TCZ.52
Clearance was 0.29 ± 0.10 mL/h/kg with the mean 
 apparent terminal half-life being 152 ± 59 hours after a 
single 10 mg/kg dose. Clearance decreased with increasing 
doses. Pharmacokinetic parameters did not change with time. 
Maximum concentration increased in a  dose- proportional 
manner. There was then a more  dose-proportional (4 mg/kg 
and 8 mg/kg every four weeks) increase seen in the area 
under the curve (AUC) and trough concentration. Comparing 
the 8 mg/kg with the 4 mg/kg dose showed an AUC 2.7-fold 
higher and trough levels 6.5-fold higher than predicted.52
The TCZ 4 mg/kg dose every four weeks produced a 
predicted mean ± standard deviation (SD) steady-state AUC, 
trough concentration, and peak level of 13,000 ± 5800 µg⋅h/mL, 
1.49 ± 2.13 µg/mL and 88.3 ± 41.4 µg/mL, respectively. 
The accumulation ratios for AUC, peak levels, and trough 
levels were 1.11, 1.02, and 1.96, respectively. All three 
parameters were higher with increased body weight. TCZ 
doses higher than 800 mg per infusion are not recom-
mended. The TCZ 8 mg/kg dose every four weeks had a 
predicted mean steady-state AUC, and peak and trough 
levels of 35,000 ± 15,500 µg⋅h/mL, 9.74 ± 10.5 µg/mL, and 
183 ± 85.6 µg/mL, respectively. The accumulation ratios 
for AUC, and peak levels and trough levels were 1.22, 1.06, 
and 2.35, respectively. All three parameters were higher with 
increased body weight.52
Study data show that RA patients had a central volume of 
distribution of 3.5 L and a peripheral volume of  distribution 
of 2.9 L, resulting in a volume of distribution at steady state of 
6.4 L. The total clearance of TCZ is concentration- dependent, 
and is determined by linear and nonlinear clearance. Linear 
clearance is estimated to be 12.5 mL/h from population 
 analysis. Low TCZ doses utilize nonlinear clearance and, 
because this becomes saturated at higher doses, linear 
clearance drives overall elimination. At steady state, the 
elimination half-life can be from 11 days (4 mg/kg every 
four weeks) to 13 days (8 mg/kg every four weeks, and is 
therefore concentration-dependent.52
There are no formal studies of the effect of hepatic or renal 
impairment on the pharmacokinetics of TCZ. Patients given 
TCZ had normal renal function, and there does not appear to 
be a need to adjust the dose for mild renal impairment.52
IL-6 reduces mRNA expression for several cytochrome 
(CYP)450 isoenzymes (CYP1A2, CYP2B6, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4) in vitro, and this is 
reversed by coincubation with TCZ at clinically relevant 
concentrations. IL-6 signal inhibition may restore CYP450 
to higher levels, thus increasing metabolism of drugs that 
are CYP450 substrates. Monitoring is recommended when 
a patient is taking a medication with a narrow therapeutic 
index (CYP450 substrate). Simvastatin and omeprazole are 
examples of medications for which TCZ administration may 
alter exposure.52
Clinical efficacy
There are six fully published Phase III studies54–59  supporting 
use of TCZ in the treatment of RA. There are also other 
 studies, including important Phase I,60 II,61–63 and III64 
 evaluations of response to TCZ by patients with active RA. 
These studies are reviewed briefly, followed by a more 
indepth summary of the fully published Phase III studies 
(Tables 1–6) for TCZ as monotherapy and in combination 
therapy.
Phase i, ii, and iii studies
A Phase I study60 explored the safety and efficacy of TCZ in 
RA patients. This was a randomized, double-blind, placebo-
controlled, dose-escalation trial in 45 patients with active RA. 
The single TCZ dose given to the study group was 0.1, 1, 5, or 
10 mg/kg. At week 2, a significant treatment difference was 
seen with the 5 mg/kg dose in regard to the American  College 
of Rheumatology 20% improvement criteria (ACR20)65 and 
disease activity score (DAS28)66 response. Diarrhea was the 
most common adverse event, with most adverse events being 
equal in both groups. This was the first randomized trial 
to show that IL-6 inhibition significantly improved signs, 
symptoms, and acute-phase reactions in RA patients.60
A Phase I/II study61 was conducted to evaluate the safety 
and efficacy of TCZ in refractory RA. This was a multicenter, 
double-blind, placebo-controlled trial in 164 patients in 
whom the study doses were 4 mg/kg and 8 mg/kg admin-
istered for three months. A dose-dependent reduction in 
ACR20 response for the 8 mg/kg dose (78%, P , 0.001) 
was higher than for the 4 mg/kg dose (57%) or placebo 
(11%) at three months. A superior response was seen in the 
8 mg/kg group for ACR50/ACR70 compared with placebo. 
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Thirty-one patients withdrew from this study, including 25 
from the placebo group. Important adverse events comprised 
a  cholesterol increase in 44% of patients, liver function dis-
orders, and decreased white blood cell counts.61
CHARISMA62 was a randomized, 16-week, Phase II, 
multicenter double-blind, placebo-controlled European trial 
in 359 patients which was done to establish the safety and 
efficacy of repeat infusions of TCZ in RA not fully respon-
sive to MTX. There were seven treatment arms comprising 
TCZ 2 mg/kg, 4 mg/kg, or 8 mg/kg, either as monotherapy 
or combination therapy with MTX, and MTX plus placebo. 
A statistically significant (P , 0.05) ACR20 was seen in 
61% and 63% of those on monotherapy (TCZ 4 mg/kg and 
8 mg/kg, respectively) and in 63% and 74% of those with the 
same TCZ dose plus MTX, respectively, compared with 41% 
receiving MTX plus placebo. As early as week 4, all study 
drug groups achieved a dose-related reduction in DAS28, 
except for the group receiving TCZ 2 mg/kg monotherapy. 
The inclusion criteria required patients to have been on 
MTX for at least four weeks; a high proportion of patients 
Table 1 Baseline characteristics from published Phase iii trials on tocilizumab monotherapy in rheumatoid arthritis
SAMURAI54 (52 wks) SATORI55 (24 wks) AMBITION56 (24 wks)
Criteria Inclusion: Age .20, RA $ 6 mos –  
5 yrs, SJC $ 6 and TJC $ 6, eSR $  
30 mm/h and CRP $ 20 mg/l, 
inadequate response to $1 DMARD or 
immunosuppressant,  wBC $ 3.5 × 109/l, 
Lymphocyte  count $ 0.5 × 109, 
Platelets $ 100 × 109 
Inclusion: Age 20–75, Treated with  
MTX (8 mg/wk) $ 8 wks until  
enrollment, RA $ 6 mos,  
inadequate response to MTX  
(SJC $ 6 + TJC $ 6 or  
eSR $ 30 mm/hr or CRP $ 10 mg/l) 
Inclusion: Age $18, Moderate 
to severe RA $ 3 mos, Active 
disease (SJC $ 6 and  
TJC $ 8 and eSR $ 28 mm/h 
or CRP $ 1 mg/dl), Stable dose  
of NSAiD and oral  
glucocorticoids $ 6 wks
Exclusion: Received anti-TNF  
and/or leflunomide #3 mos prior to 
1st dose, Change in dose and type of 
immunosuppressants/DMARDs, plasma  
exchange and surgery #4 wks prior to  
1st dose, Serious allergic reaction,  
Significant concomitant disease, Active 
infection requiring medication #4 wks  
prior to 1st dose
Exclusion: Lymphocyte count  
,0.5 × 109, wBC , 3.5 × 109/l,  
Platelets ,LLN, Failed anti-TNF  
agent or leflunomide #12 wks  
prior to study, Class iv RA, AST  
or ALT or Serum Cr .1.5-fold  
ULN, Active infection, HCv ab  
or HBs antigen +, Reaction to MTX,  
Significant disease (cardiac, blood, 
respiratory, neurologic, endocrine,  
renal, hepatic or Gi), Alcoholic
Exclusion: Unstable 
concurrent illness, Active TB, 
Failed anti-TNF agent, MTX 
use #6 months prior to study, 
MTX adverse effect or lack of 
efficacy in past
DMARDa 
(n = 143)
TCZ 8b 
(n = 157)
MTXc 
(n = 64)
TCZ 8b 
(n = 61)
MTXd 
(n = 284)
TCZ 8e 
(n = 286)
Age, years 53.1 52.9 50.8 52.6 50.0 50.7
Female, % 82 80 75 90 79 83
RA, years 2.4 2.2 8.7 8.5 6.2 6.4
DAS28 (2–10) 6.4 6.5 6.2 6.1 6.8 6.8
CRP mg/l 49 47 32 30 31 30
eSR mm/h 71.0 70.8 51.9 51.9 49.4 49.9
TJC 14.4/49 15.3/49 14.2/49 13.8/49 31.1/68 31.8/68
SJC 11.9/46 12.5/46 12.7/46 12.4/46 19.2/66 19.1/66
HAQ-Di (0–3) – – – – 1.5 1.6
Pain vAS – – – – 61.5 58.7
Patient vAS – – – – 65.6 63.9
Phys. vAS – – – – 63.6 63.0
TSS 30.6 28.3 – – – –
erosion score 13.9 13.8 – – – –
JSN score 16.7 14.5 – – – –
veGF pg/ml – – 730.8 711.3 – –
DMARD/TNF use 2.8 (1–7)f 2.7 (1–7)f 3.6 (1–8)f 3.3 (1–8)f 1.1 ± 1.4g 1.2 ± 1.3g
Notes: except where indicated otherwise, values are the mean. A blank represents no reported value. aDMARD group: MTX (30%), MTX + DMARD (37%) or DMARD and/
or immunosuppressant’s other than MTX (22%) + TCZ Placebo; bTCZ 8 mg/kg + MTX Placebo; cMTX + TCZ Placebo; dMTX (7.5–20 mg escalating dose); eTCZ 8 mg/kg; 
fNumber (range) of failed DMARDS; gMean ± SD of DMARD and anti-TNF’s used previously. 
Abbreviations: RA, rheumatoid arthritis; DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor; DAS28, disease activity score 28; SJC, swollen joint 
count; TJC, tender joint count; eSR, erythrocyte sedimentation rate; CRP, C-reactive protein; wBC, white blood cell; TCZ, tocilizumab; MTX, methotrexate; TSS, total 
sharp score; NSAID, nonsteroidal anti-inflammatory drug; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Cr, Creatinine; ULN, upper limit of normal; LLN, 
lower limit of normal; TB, tuberculosis; HCv, hepatitis C virus; HBs, hepatitis B surface; Gi, gastrointestinal; JSN, joint space narrowing; veGF, vascular endothelial growth 
factor; vAS, visual analog scale (0–100 mm); HAQ-Di, Health Assessment Questionnaire Disability index.
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Table 2 Baseline characteristics from published Phase iii trials on tocilizumab combination therapy in rheumatoid arthritis
OPTION57 (24 wks) RADIATE58 (24 wks) TOWARD59 (24 wks)
Criteria Inclusion: Adult, RA $ 6 mos, Active disease 
(SJC $ 6 + TJC $ 8 or eSR $ 28 mm/hr or 
CRP . 10 mg/l), Received MTX $ 12 wks  
(stable dose 10–25 mg/wk $8 wks) with 
inadequate response prior to study,  
Discontinued all other DMARDs (etanercept  
$ 2 wks, infliximab or adalimumab $8 wks,  
leflunomide $12 wks or $4 wks with  
colestyramine washout, anakinra $1wk),  
Stable dosage of NSAiDs and/or oral  
steroids $6 wks
Inclusion: Age $18, Moderate to severe  
RA $ 6 mos (SJC $ 6 + TJC $ 8),  
eSR $ 28 mm/h and CRP $ 1 mg/dl, Failed  
anti-TNF # 1 yr, Discontinued etanercept  
($2 wks), infliximab or adalimumab ($8 wks),  
leflunomide ($12 weeks) and all DMARDs 
(except MTX) prior to study
Inclusion: Age $18, 
Moderate to severe  
RA $ 6 mos, SJC $ 6 + 
TJC $ 8, eSR $ 28 mm/h 
or CRP $ 1 mg/dl, Stable 
dose of NSAiD/oral 
steroid $6 wks, Stable 
dose of DMARDs $  
8 wks prior to study 
(MTX, HCQ, SZA, LeF, 
gold, AZA or combination 
of 2–3 DMARDS) 
Exclusion: Class iv RA, Other autoimmune  
disease, significant systemic involvement of  
RA, other inflammatory joint disease,  
recurrent infections, AST or ALT . 1.5  
ULN, Failed anti-TNF agent
Exclusion: Cell depleting agent treatment, 
Uncontrolled medical conditions, Other 
inflammatory disease, Class IV RA, Malignancy, 
Recurrent infections, Active TB, Hepatitis B or 
C, Immunodeficient, Hemoglobin , 8.5 g/dl, 
leukopenia, neutropenia, thrombocytopenia, 
Triglycerides . 10 mmol/l, Liver disease
Exclusion: Failed anti-
TNF, cell depleting agent 
treatment, Failed TB 
screen per local practice
MTXa 
(n = 204)
TCZ 4b 
(n = 213)
TCZ 8c 
(n = 205)
MTXa 
(n = 158)
TCZ 4b 
(n = 161)
TCZ 8c 
(n = 170)
DMARDd 
(n = 413)
TCZ 8e 
(n = 803)
Age, years 50.6 51.4 50.8 53.4 50.9 53.9 54 53
Female, % 78 82 85 79 81 84 84 81
RA, years 7.8 7.4 7.5 11.4 11. 12.6 9.8 9.8
DAS28 (2–10) 6.8 6.8 6.8 6.80 6.78 6.79 6.6 6.7
CRP mg/l 24 28 26 37 31 28 26 26
eSR mm/h 49.7 49.2 51.2 54.6 51.3 49.1 49.2 48.2
TJC 32.8/68 33.2/68 31.9/68 30.4 31.3 31.7 29.1/66 30.1/66
SJC 20.7/66 20.0/66 19.5/66 18.9 19.5 18.9 18.7/68 19.7/68
HAQ-Di (0–3) 1.5 1.6 1.6 1.7 1.7 1.7 1.5 1.5
SF-36 physical 32.3 31.5 32.7 – – – – –
SF–36 mental 39.1 40.1 40.9 – – – – –
FACiT (0–52) 26.7 27 27.7 – – – – –
Pain vAS 57.3 60.7 59.9 64.1 63.5 64.7 59 58
Patient vAS 63.6 65.6 64.8 70.9 70.4 70.2 66 66
Phys. vAS 63.7 63.6 64 67.5 66.5 66.4 63 64
MTX, mg 14.8 14.7 14.5 16.5 16.2 15.7 15.0 14.7
DMARD use 1.7 ± 1.5f 1.5 ± 1.4f 1.5 ± 1.4f 2.1 ± 1.6f 2.0 ± 1.6f 1.9 ± 1.7f 1.6 ± 1.6g 1.6 ± 1.6g
TNF use 19 (9%)h 21 (10%)h 11 (55%)h 30.6%i  
39.4%j  
29.4%k
38.0%i  
34.4%j  
26.4%k
38.3%i  
30.3%j  
31.4%k
Notes: except where indicated otherwise, values are the mean. A blank represents no reported value. aMTX 10–25 mg + TCZ placebo; bTCZ 4 mg/kg + MTX 10–25 mg; 
cTCZ 8 mg/kg + MTX 10–25 mg; dPermitted DMARD + TCX placebo; ePermitted DMARD + TCX 8 mg/kg; fMean ± SD of DMARDS used before study; gMean ± SD of 
DMARD plus anti-TNF’s used previously; hNumber (%) of total that used anti-TNF’s previously; iPercent with previous etanercept use; jPercent with previous Adalimumab 
use; kPercent with previous Infliximab use.
Abbreviations: RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; MTX, methotrexate; eSR, erythrocyte sedimentation rate; CRP, C-reactive 
protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TNF, tumor necrosis factor; DMARD, disease-modifying antirheumatic drug; TB, tuberculosis; 
NSAID, nonsteroidal anti-inflammatory drug; ULN, upper limit of normal; HCQ, hydroxychloroquine; SZA, sulfasalazine; LEF, leflunomide; AZA, azathioprine; 
TCZ, Tocilizumab; DAS28, disease activity score 28; HAQ-Di, Health Assessment Questionnaire Disability index; SF36, Short Form 36 (scored 0–100); FACiT, Functional 
Assessment of Chronic illness Therapy; vAS, visual analog scale (0–100 mm).
in the placebo group responded to MTX, demonstrating 
there was not an initial “incomplete response”. Important 
adverse events were a rise in alanine transaminase, aspartate 
transaminase, total cholesterol, and triglyceride levels. There 
was a reduction in neutrophil levels.62
STREAM63 was a long-term extension of the three-month 
study61 described above, and evaluated the safety and efficacy 
of TCZ 8 mg/kg monotherapy for five years in 143 patients. 
Forty-eight patients had withdrawn from the study (32 due 
to adverse events and one due to a poor response). The 
serious adverse event rate was 27.5 events per 100 patient-
years, with 5.7 serious infections per 100 patient-years. 
ACR20, 50, and 70 responses at five years analyzed by 
last observation carried forward were 77%, 59%, and 38%, 
Drug Design, Development and Therapy 2010:4
Table 3 Clinical response from Phase iii trials on tocilizumab monotherapy in rheumatoid arthritis
SAMURAI54 (52 wks) SATORI55 (24 wks) AMBITION56 (24 wks)
DMARDa 
(n = 143)
TCZ 8b 
(n = 157)
MTXc 
(n = 64)
TCZ 8b 
(n = 61)
MTXd 
(n = 284)
TCZ 8e 
(n = 286)
ACR20 34 78* 25 80* 53 70*
ACR50 13 64* 11 49* 34 44**
ACR70 6 44* 6 30* 15 28*
DAS28 ,2.6 3 59* 1.6 43.1* 12 34$
eULAR response – – 39.7 96.6 64.8 82.2
CRP mg/l – – – – -1.9 -2.8$$
eSR mm/h – – – – -16.1 -37.3$$
TJC – – – – -13.9 -17.2$$
SJC – – – – -8.2 -11.7$$
HAQ-Di – – – – -0.5 -0.7$$
Pain vAS – – – – -29.9 -31.9
Pt. vAS – – – – -30.7 -34.5
Phys vAS – – – – -31.7 -41.3$$
TSS 6.1 2.3# – – – –
erosion score 3.2 0.9* – – – –
JSN score 2.9 1.5## – – – –
veGF pg/ml – – -74.0 -346.9* – –
MHAQ (↓$0.22) 40 68* 34 67* – –
Notes: ACR20, 50, 70, DAS28, eULAR response (good+moderate) and MHAQ are all shown as proportion of patients who achieved response CRP, eSR, TJC, SJC, HAQDi, 
vAS, TSS, erosion score, JSN score are all shown as mean change from baseline A blank represents no reported value. *P , 0.001; **P = 0.002; #P , 0.01; ##P , 0.05; $Odds 
ratio vs MTX: 5.83; 95% Ci 3.27 to 10.40; $$Superiority criteria met aDMARD group: MTX (30%), MTX + DMARD (37%) or DMARD and/or immunosuppressant’s other 
than MTX (22%) + TCZ Placebo; bTCZ 8 mg/kg + MTX Placebo; cMTX + TCZ Placebo; dMTX (7.5–20 mg escalating dose); eTCZ 8 mg/kg.
Abbreviations: ACR20,50,70, American College of Rheumatology 20%, 50%, 70% improvement criteria; DAS28, disease activity score 28 (,2.6 indicates remission); 
eULAR, european League Against Rheumatism (good+moderate); CRP, C-reactive protein; eSR, erythrocyte sedimentation rate; TJC, tender joint count; SJC, swollen joint 
count; HAQ-Di, Health Assessment Questionnaire-Disability index (scored 0–3); TSS, Total Sharp score; vAS, visual analog scale (scored 0–100 mm); JSN, joint space 
narrowing score; VEGF, vascular endothelial growth factor; MHAQ, Modified Health Assessment Questionnaire (↓ of $0.22 is significant clinical improvement).
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respectively. Corticosteroid doses were decreased in 89% of 
patients. A remission (disease activity score , 2.6) was seen 
in 55% of patients. This was the first study to demonstrate 
the long-term safety and efficacy of TCZ monotherapy in 
DMARD-resistant disease. Total cholesterol elevation was 
seen throughout the study period, and there was one episode 
of ischemic heart disease in a patient who also had diabetes 
mellitus. Mean neutrophil counts decreased but remained 
in the normal range. There was no significant liver disease 
seen, despite slight elevations of mean alanine transaminase 
and aspartate transaminase values.63
LITHE64 was a Phase III, international (15 countries), 
randomized, double-blind, placebo-controlled study of TCZ 
in patients with moderate to severe RA who remained on 
MTX despite inadequate response. Patients received TCZ 
4 mg/kg or 8 mg/kg, or placebo, with background MTX 
(52 weeks with rescue at 16 weeks if needed). All patients 
were to take TCZ 8 mg/kg for the second year unless they 
achieved $70% improvements in swollen joint count and 
tender joint count. A primary endpoint at week 104 was 
change from baseline in Genant-modified Total Sharp Score, 
which showed that there was significantly less radiographic 
progression in the TCZ 8 mg/kg group compared with 
 placebo. There were  significantly more TCZ 8 mg/kg patients 
than those on placebo with no radiographic progression 
(P # 0.0001). The change from baseline Health Assessment 
Questionnaire-Disability Index (HAQ-DI)67 was significant 
in both TCZ groups when compared with placebo. From the 
data presented, serious adverse events are comparable in all 
three groups, but the results of this study have not been fully 
published at the time of writing.
Fully published Phase III trials are now described. 
Baseline data, as well as inclusion and exclusion criteria, 
for each study are summarized in Tables 1 and 2. Some of 
the patients enrolled had a history of previous use and/or 
failure of DMARDs and TNF-α inhibitors, except for those 
in the AMBITION study. The duration of each trial ranges 
from 24–52 weeks. Important efficacy outcomes are sum-
marized in Tables 3 and 4. ACR20 was the primary endpoint 
in all studies, except for SAMURAI, ie, the only study that 
investigated patients with early RA. All the studies described 
had the primary efficacy endpoint analyzed in the intention-
to-treat population with last observation carried forward, 
except for AMBITION; noninferiority on the per-protocol 
Drug Design, Development and Therapy 2010:4
Table 4 Clinical response from the Phase iii trials on tocilizumab combination therapy in rheumatoid arthritis
OPTION57 (24 wks) RADIATE58 (24 wks) TOWARD59 (24 wks)
MTXa 
(n = 204)
TCZ 4b  
(n = 213)
TCZ 8c 
(n = 205)
MTXa 
(n = 158)
TCZ 4b 
(n = 161)
TCZ 8c 
(n = 170)
DMARDd 
(n = 413)
TCZ 8e 
(n = 803)
ACR20 26 48* 59* 10.1 30.4** 50.0** 24.5 60.8*
ACR50 22 31* 44* 3.8 16.8** 28.8** 9.0 37.6*
ACR70 4 12* 22* 1.3 5.0 12.4# 2.9 20.5*
DAS28 ,2.6 0.8 13** 27* 1.6 7.6 30.1# 3 30*
eULAR response 33 62* 79* 16.5 46.5** 67.7** 38 80*
CRP mg/l -3.5 -16.6** -25.1* – – – -2.7 -22*
eSR mm/h -7.1 -25.5* -39.5* – – – -4.7 -35.6*
TJC -7.4 -14.5* -17.1* -0.3 -10.5** -14.8** -8.5 -15.7*
SJC -4.3 -8.5* -10.5* -0.5 -6.8** -7.8** -4.9 -10.3*
HAQ-Di -0.34 -0.52## -0.055# -0.05 -0.31** -0.39** -0.2 -0.5*
SF-36 physical 5.0 9.7* 9.5* – – – 4.1 8.9*
SF-36 mental 2.7 5.7## 7.3# – – – 2.3 5.3*
FACiT 4.0 7.3# 8.6* – – – 3.6 8.0*
Pain vAS -14.0 -25.0** -29.8* – – – – –
Pt. vAS -17.8 -28.8** -32.7* – – – – –
Phys vAS -32.7 -38.3## -41.6** – – – – –
Notes: ACR20, 50, 70, DAS28 and eULAR response (good+moderate) are all shown as proportion of patients who achieved response CRP, eSR, TJC, SJC, HAQDi, SF36, 
FACiT and vAS are all shown as mean change from baseline A blank represents no reported value. *P , 0.0001; **P , 0.001; #P , 0.01; ##P , 0.05; aMTX 10–25 mg + TCZ 
placebo; bTCZ 4 mg/kg + MTX 10–25 mg; cTCZ 8 mg/kg + MTX 10–25 mg; dPermitted DMARD + TCX placebo; ePermitted DMARD + TCX 8 mg/kg.
Abbreviations: ACR20,50,70, American College of Rheumatology 20%, 50%, 70% improvement criteria; DAS28, disease activity score 28 (,2.6 indicates remission); 
eULAR, european League Against Rheumatism (good+moderate); CRP, C-reactive protein; eSR, erythrocyte sedimentation rate; TJC, tender joint count; SJC, swollen joint 
count; HAQ, Health Assessment Questionnaire Disability index (scored 0–3); SF36, Short Form 36 (scored 0–100); FACiT, Functional Assessment of Chronic illness Therapy 
(scored 0–100); vAS, visual analog scale (scored 0–100 mm).
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population and superiority on the intention to treat. The 
 baseline  characteristics and demographics in each study were 
not different between the study and placebo groups.
Tocilizumab monotherapy  
in rheumatoid arthritis
AMBITION56 was a 24-week, Phase III, international (US, 
Canada, and Israel), randomized, double-blind, double-
dummy, placebo-group study evaluating the efficacy and 
safety of TCZ monotherapy versus MTX in patients with 
active RA for whom previous therapy with MTX and/
or  biologic agents had not failed. Patients were randomly 
assigned to two groups. One groups received TCZ 8 mg/kg 
intravenously every four weeks (n = 288) and the second 
group received MTX (escalating dose regimen, ie, initially 
7.5 mg, increasing to 15 mg at week 4 and 20 mg at week 8) 
orally once weekly (n = 288). There was a substudy arm 
which is not reviewed here. In total, 673 patients were ran-
domized, with most completing the study (93% in the TCZ 
group and 92% in the MTX group)
The primary endpoint was ACR20 response at week 24. 
The primary efficacy analysis was a noninferiority compari-
son using the established per-protocol population (ACR20 
70.6% for TCZ versus 52.1% for MTX). Superiority of TCZ 
to MTX was shown in the intention-to-treat population as 
early as week 2, with an increase over time (ACR20 69.6% 
for TCZ versus 52.5% for MTX, P , 0.001 at week 24). 
Important secondary endpoints (Table 3) analyzed by 
superiority in the intention-to-treat population included 
the proportion of those with an ACR50/ACR70 response 
at week 24. Changes from baseline in DAS28,66 inflamma-
tory markers, and HAQ-DI were assessed at week 24. The 
proportion of those with clinical remission (DAS28 , 2.6) 
and a good/moderate European League Against Rheumatism 
(EULAR) response68 was also assessed. Pain and patient’s 
global assessment of disease activity were measured using 
a visual analog scale.69
SATORI55 was a 24-week, multicenter, randomized, 
double-blind, placebo-controlled Japanese study evaluating 
the efficacy and safety of TCZ monotherapy in patients with 
active RA AND an inadequate response to MTX. Patients 
were randomly assigned to one of two groups. One group 
received TCZ 8 mg/kg intravenously every four weeks plus 
an MTX placebo weekly (n = 61) and the second group 
received TCZ or placebo intravenously every four weeks plus 
MTX 8 mg orally weekly (n = 66). A total of 127 patients 
were randomized, with 88 completing the study (89% in the 
TCZ group and 52% in the MTX group).
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Table 5 Adverse events from Phase iii trials on tocilizumab monotherapy in rheumatoid arthritis
SAMURAI54 (52 wks) SATORI55 (24 wks) AMBITION56 (24 wks)
DMARDa 
(n = 143)
TCZ 8b 
(n = 157)
MTXc 
(n = 64)
TCZ 8b 
(n = 61)
MTXd 
(n = 284)
TCZ 8e 
(n = 286)
Any adverse event 82 89 72 92 78 80
Serious adverse event 13 18 4.7 6.6 3 4
Related serious adverse event – – – – 1 1
Ae leading to discontinuation – – – – 5 4
AE leading to dose modification – – – – 22 19
Death – – – – ,1 1
AE’s in $5% AE’s in .5% AE’s in $5%
infections and infestations – – – – 37 34
 Nasopharyngitis 32 36 11 18 6 7
 Upper respiratory tract infections – – 6 5 5 7
 Stomatitis – – 0 12 – –
Gastrointestinal disorders – – – – 31 30
 Nausea 1 6 – – 12 6
 vomiting 3 5 – – – –
 Diarrhea 9 8 2 7 5 5
MSK + CT disorders – – – – 11 12
Skin and SC tissue disorders – – – – 11 15
 Rash 4 11 – – – –
 eczema 4 6 – – – –
 Paronychia ,1 6 – – – –
Nervous system disorders – – – – 6 13
 Headaches 2 7 3 7 3 7
Laboratory investigations 31 61 23 56 15 17
injury and procedural – – – – 5 5
vascular disorders – – – – 5 8
Psychiatric disorders – – – – 7 7
eye disorders – – – – 3 5
Respiratory, thoracic and mediastinal disorders – – – – 7 9
General disorders and administrative-site conditions 0 7f 0 12f 9 7
SAE’s in .1% SAE’s in .1% SAE’s in .1%
infections and infestations 5.6 7.6 1.6 3.2 0.7 1.4
Spinal compression fracture 5.5 1.9 1.6 – – –
Femoral neck fracture – – 1.6 – – –
Malignancy 0 1.9 – – 1.1 0.3
Notes: values are the percent of patients rounded to nearest whole number for Ae and the nearest one tenth for SAe. A blank represents no reported value. aDMARD 
group: MTX (30%), MTX + DMARD (37%) or DMARD and/or immunosuppressant’s other than MTX (22%) + TCZ Placebo; bTCZ 8 mg/kg + MTX Placebo; cMTX + TCZ 
Placebo; dMTX (7.5–20 mg escalating dose); eTCZ 8 mg/kg; finfusion reactions.
Abbreviations: Ae, adverse event; SAe, serious adverse event; MSK, musculoskeletal; CT, connective tissue; SC, subcutaneous.
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The primary endpoint was ACR20 response at week 
24 (80.3% for TCZ versus 52.5% for placebo, P , 0.001). 
Important secondary endpoints (Table 3) were the propor-
tion of those with an ACR50/ACR70 response at week 
24. Change from baseline in the DAS28, Modified Health 
Assessment Questionnaire (to represent significant clinical 
improvement),70 the proportion of those with clinical remis-
sion (DAS28 , 2.6), and good/moderate EULAR responses 
was assessed. Mean serum vascular endothelial growth factor 
was also checked in both groups.
SAMURAI54 was a 52-week, Phase III, multicenter, rand-
omized, x-ray reader-blinded, controlled Japanese  evaluation 
of the ability of TCZ monotherapy to inhibit progression of 
structural joint damage in patients with early RA. Patients 
were randomly assigned to two groups. One groups received 
TCZ 8 mg/kg intravenously every four weeks (n = 158) and the 
 second group received conventional DMARD therapy (n = 148); 
30% were on MTX monotherapy, 37% were on a combination 
of MTX and DMARDs, and 22% were on DMARDs and/or 
immunosuppressants other than MTX. A total of 306 patients 
were randomized, with 265  completing the study (85% in the 
TCZ group and 90% in the DMARD group).
The primary endpoint (Table 3) was changes in radio-
graphic disease progression, and significantly less  progression 
Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
271
Tocilizumab for rheumatoid arthritis
was seen in the TCZ group compared with the placebo group. 
Radiographic endpoints on modified Total Sharp Score,71 ero-
sion score, and joint space narrowing were assessed with a 
rank-transformed analysis of covariance on the change scores 
that included factors for baseline score and disease duration. 
ACR20, 50, and 70 responses, DAS28, and Modified Health 
Assessment Questionnaire scores were assessed using the 
intent-to-treat analysis.
Combination therapy  
with tocilizumab and DMARDs
OPTION57 was a 24-week, Phase III, international (17 
countries), randomized, double-blind, placebo-controlled, 
parallel group study of the efficacy and safety of TCZ in 
patients with active RA receiving background MTX therapy. 
Patients were randomly assigned to one of three groups. 
Two groups received TCZ intravenously every four weeks, 
ie, 4 mg/kg (n = 214) or 8 mg/kg (n = 205) plus MTX orally 
weekly (stable dose 10–25 mg). The third group received 
TCZ  placebo intravenously every four weeks plus MTX 
orally weekly (stable dose 10–25 mg, n = 204). Patients could 
be enrolled on rescue therapy of TCZ 8 mg/kg at week 16. 
A total of 623 patients were randomized, with 566 complet-
ing the study, including 111 on rescue therapy. Ninety-three 
percent, 87%, and 93% in the TCZ 8 mg/kg, TCZ 4 mg/kg 
and placebo groups, respectively, completed the study.
The primary endpoint was ACR20 response at week 24, 
which was 59% for TCZ 8 mg/kg versus 26% for placebo 
(P , 0.001) and 48% for TCZ 4 mg/kg versus 26% for pla-
cebo (P , 0.001). Important secondary endpoints (Table 4) 
were the proportion of patients with an ACR50/ACR70 
response at week 24, change from baseline in DAS28, the 
proportion of those with a clinical remission (DAS28 , 2.6), 
and a good/moderate EULAR response at week 24. Pain 
and patient’s global assessment of disease activity were 
measured by a visual analog scale. HAQ-DI was used to 
Table 6 Adverse events reported from the Phase iii trials on tocilizumab combination therapy in rheumatoid arthritis
OPTION57 (24 wks) RADIATE58 (24 wks) TOWARD59 (24 wks)
MTXa 
(n = 204)
TCZ 4b 
(n = 212)
TCZ 8c 
(n = 206)
MTXa 
(n = 158)
TCZ 4b 
(n = 161)
TCZ 8c 
(n = 170)
DMARDd 
(n = 414)
TCZ 8e 
(n = 802)
Any adverse event 63 71 69 81 87 84 61 73
Serious adverse event – – – 11 7 6 4f 7f
Related serious adverse event – – – 2 2 3 1 3
Ae leading to discontinuation – – – 5 6 6 2 4
AE leading to dose modification – – – 8 15 7 7 14
Death – – – 0 0 0 ,1 ,1
AE’s in $5% AE’s in .5% AE’s in $5%
infections and infestations 27 31 32 41 47 49 32 37
Gastrointestinal disorders 22 22 23 19 33 37 15 21
MSK + CT disorders 16 14 12 21 21 15 18 13
Skin and SC tissue disorders 7 13 18 14 31 22 7 17
Nervous system disorders 13 12 15 17 20 18 9 12
Laboratory investigations 5 12 15 – – – 3 12
injury and procedural – – – 10 7 11 7 8
vascular disorders 5 8 6 5 11 8 5 7
Psychiatric disorders – – – 4 10 7 – –
eye disorders – – – 2 7 6 – –
Metabolism and nutrition – – – 4 4 5 – –
Hematologic – – – 3 3 5 – –
Respiratory, thoracic and 
mediastinal disorders
5 7 8 13 15 12 5 9
General disorders and 
administrative-site conditions
7 9 11 14 16 12 7 8
SAE’s in .1% SAE’s in .1% SAE’s in .1%
infections and infestations 1.0 1.4 2.9 3.1 1.8 4.6 1.9 2.7
Gastrointestinal disorders – – – 1.3 1.2 1.1 0.2 1.1
MSK + CTD disorders – – – 3.1 1.2 0.6 – –
Notes: values are the percent of patients rounded to nearest whole number for Ae and the nearest one tenth for SAe. A blank represents no reported value. aMTX 
10–25 mg + TCZ placebo; bTCZ 4 mg/kg + MTX 10–25 mg; cTCZ 8 mg/kg + MTX 10–25 mg; dPermitted DMARD + TCX placebo ePermitted DMARD + TCX 8 mg/kg; 
fvalues represent % of SAe occurring in $ 3 patients.
Abbreviations: Ae, adverse event; SAe, serious adverse event; MSK, musculoskeletal; CT, connective tissue; SC, subcutaneous.
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assess physical function. The Short-Form 36 Health Survey 
(SF-36)72 and Functional Assessment of Chronic Illness 
Therapy (FACIT)-Fatigue assessment73 was used to assess 
health-related quality of life.
TOWARD59 was a 24-week, international (18 countries), 
randomized, double-blind, placebo-controlled study which 
investigated the efficacy and safety of TCZ combined with 
conventional DMARDs in patients with active RA. Patients 
were randomly assigned in a ratio of 2:1 to two groups. One 
group received TCZ 8 mg/kg intravenously every four weeks 
plus stable DMARD therapy (n = 805). The second group 
received TCZ placebo intravenously every four weeks plus 
stable DMARD therapy (n = 415). Patients could be enrolled 
in rescue therapy (adjustment/change of DMARD and/or 
glucocorticoids) at week 16. A total of 1220 of patients were 
randomized, with 91% in the TCZ group and 78% in the 
placebo group completing the study.
The primary endpoint was ACR20 response at week 
24 (61% for TCZ 8 mg/kg versus 25% for placebo, 
P , 0.0001). Important secondary endpoints (Table 4) were 
the proportion of those with an ACR50/ACR70 response 
at week 24, change from baseline of the DAS28, the pro-
portion of those with a clinical remission (DAS28 , 2.6) 
and a good/ moderate EULAR response at week 24. The 
HAQ-DI was used to assess physical function. The SF-36 
and  FACIT-Fatigue assessment was used to assess health-
related quality of life.
RADIATE58 was a 24-week, international (US and 
 Western Europe), randomized, double-blind, placebo-
controlled, parallel-group Phase III evaluation of the efficacy 
and safety of TCZ in patients with active RA refractory to 
TNF-α inhibitor therapy. Patients were randomly assigned 
to three groups. Two groups received TCZ intravenously 
every four weeks, ie, 4 mg/kg (n = 163) or 8 mg/kg (n = 175) 
plus MTX orally weekly (stable dose 10–25 mg). The third 
group received TCZ placebo intravenously every four weeks 
plus MTX orally weekly (stable dose 10–25 mg, n = 160). 
Patients could be allocated to rescue therapy (TCZ 8 mg/kg 
plus MTX) at week 16. A total of 498 patients were random-
ized, with 417 completing the study and 113 being switched 
to rescue therapy. Within the study groups, 75%, 66%, and 
40% in the TCZ 8 mg/kg, TCZ 4 mg/kg, and placebo groups, 
respectively, completed the study.
The primary endpoint was ACR20 response at week 24 
(50% for TCZ 8 mg/kg versus 10.1% for placebo [P , 0.001] 
and 30.4% for TCZ 4 mg/kg versus 10.1% for placebo 
[P , 0.001]). Important secondary endpoints (Table 4) were 
the proportion of patients with an ACR50/ACR70 response at 
week 24, change from baseline of the DAS28, the proportion 
of those with clinical remission (DAS28 , 2.6) and a good/
moderate EULAR response at week 24. The HAQ-DI was 
used to assess physical function.
Safety and tolerability
Data on adverse events and serious adverse events from the 
six fully published trials54–59 are shown in Tables 5 and 6. The 
TCZ prescribing information52 includes combined safety data 
from five trials,56–59,64 ie, TCZ 4 mg/kg in combination with 
MTX (n = 774), TCZ 8 mg/kg monotherapy (n = 288), and 
TCZ 8 mg/kg in combination with DMARDs (n = 1582). All 
patients in the registration studies who received at least one 
dose of TCZ have been included in the exposure population 
(n = 4009). Treatment was given to 3577 of these patients 
for at least six months. The study population was of mean 
age 52 years, with 82% being female and 74% Caucasian, 
and having moderate to severe active RA.52
The most commonly reported adverse events (occurring 
in $5% of patients on TCZ monotherapy and combination 
therapy) in the controlled studies56–59,64 up to six months 
were upper respiratory tract infections, nasopharyngitis, 
headache, hypertension, and increased alanine transaminase. 
Increased transaminase values and serious infections were 
the most common reason for discontinuation of the medica-
tion (5% for patients taking TCZ and 3% for patients taking 
placebo).52,56–59,64 The medication was generally well tolerated 
at doses of 4 mg/kg and 8 mg/kg given every four weeks.
Infections occurred at a rate of 119 events per 100 patient-
years in the TCZ monotherapy group, which was similar to 
the rate in the MTX monotherapy group. The TCZ-DMARD 
combination group (4 mg/kg with 133 events and 8 mg/kg 
with 127 events) had events per 100 patient-years similar to 
those of the placebo-DMARD group (112 events). Upper 
respiratory tract infection and nasopharyngitis were the most 
commonly reported infections. The overall rate of infections 
with TCZ in the all-exposure population was 108 events per 
100 patient-years.52,56–59,64
The most common serious infections were  pneumonia, 
urinary tract infection, cellulitis, herpes zoster,  gastroenteritis, 
diverticulitis, sepsis, and bacterial arthritis. The rate of  serious 
infections in the TCZ monotherapy group was 3.6 per 100 
patient-years compared with 1.5 per 100  patient-years in the 
MTX group. The TCZ-DMARD combination group (4 mg/kg 
with 4.4 events and 8 mg/kg with 5.3 events) had events per 
100 patient-years similar to that in the  placebo-DMARD 
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group (3.9 events). The all-exposure population had an 
overall rate of serious infections of 4.7 events per 100 
 patient-years. The overall rate of fatal serious infections was 
low (0.13 per 100 patient-years).52,56–59,64
Infusion-related events were reported in 8% of patients 
on the 4 mg/kg TCZ-DMARD) combination, 7% on the 
8 mg/kg TCZ-DMARD combination, and 5% on the placebo-
DMARD combination. Headache and skin reactions were the 
most commonly reported events within the first 24 hours of 
infusion. Hypertension was reported by 1% for both doses of 
TCZ during the infusion. A clinically significant hypersensi-
tivity reaction was documented in 0.2% of patients (9/4009) 
in the all-exposure population and this was usually observed 
during the second, third and/or fourth infusions. Anti-TCZ 
antibodies developed in 2% of patients (46/2876), and five 
had to withdraw from their allocated treatment because of a 
hypersensitivity reaction.52,56–59,64
Gastrointestinal perforations occurred at a rate of 0.26 
events per 100 patient-years with TCZ therapy in the controlled 
clinical trials.52,56–59,64 Most of the patients who developed this 
complication were also taking nonsteroidal anti-inflammatory 
drugs, corticosteroids, and/or MTX, but whether this played 
a role in the gastrointestinal problems is not known. The all-
exposure population had an overall rate of 0.28 events per 100 
patient-years for gastrointestinal perforation.
A decrease in neutrophil counts (,1000/mm3) occurred in 
1.8% (TCZ 4 mg/kg), and 3.4% (TCZ 8 mg/kg) in the com-
bination DMARD group.52,56–59,64 The placebo group had only 
0.1% of patients with low neutrophil counts. A decrease in 
counts below 500/mm3 occurred in 0.4%, 0.3%, and 0.1% of 
patients in the 4 mg/kg and 8 mg/kg TCZ and placebo groups 
(all with combination DMARDs), respectively. Platelets were 
also decreased (,100,000/mm3) as a result of TCZ-DMARD 
therapy in 1.3% (4 mg/kg) and 1.7% (8 mg/kg) of patients. 
Only 0.5% of patients in the placebo group developed a 
reduction in platelets, with no bleeding events in any of the 
groups. The all-exposure population had similar patterns as 
seen in the controlled trials.52,56–59,64
Reduction in the TCZ dose, interruption of TCZ treat-
ment, or a reduced dose of DMARDs was needed in some 
patients because of liver enzyme abnormalities. There were 
more patients on a TCZ-DMARD combination than on TCZ 
monotherapy (8 mg/kg) or MTZ monotherapy who had eleva-
tions in aspartate transaminase and alanine transaminase.52
An elevation of lipids was seen at week 6, but these 
levels stabilized at this point and were responsive to lipid-
lowering agents. The mean LDL increased by 13 mg/dL (TCZ 
4 mg/kg + DMARD), 20 mg/dL (TCZ 8 mg/kg + DMARD), 
25 mg/dL (TCZ 8 mg/kg monotherapy), and mean HDL 
increased by 3 mg/dL (TCZ 4 mg/kg + DMARD), 5 mg/dL 
(TCZ 8 mg/kg + DMARD), 4 mg/dL (TCZ 8 mg/kg mono-
therapy) in the controlled trials.52,56–59,64
Malignancy developed in 15 patients in the TCZ groups 
compared with eight patients in the control groups. The 
exposure-adjusted incidence was 1.32 events per 100 patient-
years for the TCZ groups and 1.37 events per 100 patient-
years for placebo-DMARD groups. A pooled analysis of 
long-term extension studies has not shown any new safety 
concerns in patients who have received this medication for 
an average of 2.4 years.74
Warnings and precautions
TCZ should not be administered to those with active infec-
tion, those exposed to tuberculosis, or those with a history of 
serious or opportunistic infection. There is an increased risk 
of gastrointestinal perforation, and patients should seek medi-
cal attention for any new onset abdominal pain. Neutropenia, 
thrombocytopenia, elevated liver enzymes, and increased 
lipid parameters are all associated with TCZ use. Laboratory 
values should be monitored every 4–8 weeks. Although the 
exact overall adverse impact of TCZ is not known, other 
warnings include risk of malignancy, hypersensitivity reac-
tions, demyelinating disorders, hepatic impairment, and, of 
course, caution with live vaccinations.52
Regulatory progress
TCZ has been approved in the US as monotherapy and in 
combination with MTX for the treatment of moderate to 
severely active RA in patients who have had an inadequate 
response to one or more TNF-α inhibitors.18 The recom-
mended dose is 4 mg/kg, with an increase to 8 mg/kg based 
on response, given every four weeks.52 The medication is also 
approved in Europe for the treatment of RA in those who have 
either responded inadequately to, or who were  intolerant of, 
previous therapy with one or more DMARDs or a TNF-α 
inhibitor.19 TCZ is also approved in many other coun-
tries, including Japan, Mexico, India, Brazil,  Switzerland, 
 Australia, and the United Arab Emirates.75
Conclusion
This review has summarized the available evidence from 
randomized controlled trials of IL-6 inhibition in the 
treatment for RA. TCZ is effective in a number of patient 
groups with active RA, and has demonstrated significant 
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clinical  improvement in ACR response rates, individual 
ACR  components, patient reported outcomes, radiographic 
progression, and DAS28 scores. Significant efficacy has been 
seen with both the 4 mg/kg and 8 mg/kg doses given every 
four weeks when compared with placebo.
TCZ monotherapy was superior to MTX monotherapy 
in those who had not had prior treatment failure and was 
significantly more effective then DMARDs in those who 
had prior treatment failure. Combination therapy with TCZ 
and MTX-DMARDs was significantly more effective than 
MTX or DMARDS as monotherapy. TCZ was also signifi-
cantly effective in those who had previously failed a TNF-α 
inhibitor. Disease activity decreased and the quality of life 
improved in those who received TCZ, and there was sustain-
ability of response shown in an extension trial. While show-
ing efficacy as monotherapy and combination therapy with 
conventional DMARDs, the medication was generally well 
tolerated. Most of the adverse events were mild to moderate 
and comparable with placebo. The trials reviewed support 
the use of TCZ in active RA.
Expert commentary
The randomized controlled trials reviewed show the benefit 
of TCZ in active RA at the approved dose of 4–8 mg/kg every 
four weeks with or without combination MTX/DMARDs. 
The benefit of having a drug administered monthly as 
opposed to weekly or biweekly is an attractive option for 
patients and clinicians. Regarding the dose, when compared 
with placebo, TCZ patients were more likely to achieve higher 
ACR response rates with the 8 mg/kg dose than with the 
4 mg/kg dose, and with similar adverse events.
TCZ is approved for use as monotherapy, as well as con-
comitantly with MTX/DMARDs in patients who have an inad-
equate response to a TNF -α inhibitor. DMARD combination 
therapy with biologics14,21,76 as well as biologic monotherapy77–79 
has been shown to treat RA effectively in previous studies. It 
would be helpful to have a comparison of TCZ monotherapy 
with combination TCZ plus MTX. As monotherapy, this medi-
cation can be an option for those who cannot tolerate MTX 
unless the reason for intolerance is liver disease. If tolerability 
issues with MTX do not exist, most clinicians would consider 
continuing a patient on MTX when adding TCZ.
The radiographic progression was less in the TCZ group 
compared with placebo. However, this was only shown in one 
fully published monotherapy study.54 Data from the LITHE 
study has been shown at national conferences, and the fully 
published study is anticipated, and will reinforce the effect 
of TCZ on radiographic measures in RA.
The TCZ studies reviewed here used varying doses of 
MTX and this does limit comparison between the studies. 
Some of the patients were on low MTX doses that most 
clinicians would have titrated higher in a real world setting. 
This may have falsely placed some patients in a nonresponder 
group.
TCZ was effective in a fashion similar to the other 
approved biologic agents when compared with placebo. 
Bergman et al80 felt that the response was comparable with 
that of other biologic agents for ACR20 and ACR50, but 
greater for ACR70. However, it is difficult to compare TCZ 
with other biologics in previous studies because there are 
limitations to comparing separate studies with different 
populations and procedures. Comparison of different stud-
ies may hold more weight if a continuous response measure, 
such as DAS28, was used, but this was not available in all 
the compared trials. A head-to-head trial comparison of 
IL-6 inhibition and TNF-α inhibition would be interesting 
and help answer some questions regarding which therapies 
to resort to when conventional DMARDs fail.
The RADIATE58 study demonstrated TCZ efficacy after 
the failure of a TNF-α inhibitor, which is now the approved 
indication in the US and UK. It would be interesting to see 
how effective this medication is in those who have failed other 
biologics (abatacept and rituximab), as well as in patients 
stratified according to the DMARD they have failed. AMBI-
TION56 was the first to show biologic monotherapy superi-
ority to MTX. There were a limited number of MTX-naïve 
patients in all these studies, and this will be an interesting 
group to look at in a future trial.
An advantage over some TNF inhibitors is that tubercu-
losis does not seem to be a safety issue because IL6 does not 
seem to have an effect on granuloma formation. All but one 
of the studies reviewed had the ACR20 as the primary out-
come; this may have underestimated the difference between 
groups in terms of adverse events. Overall, the medication 
was safe to use as there were minimal adverse events and 
serious adverse events. However, future studies should be 
considerably longer, with a larger population, and include 
safety as a primary outcome. The study populations reported 
here did not have much comorbidity because these patients 
were excluded; safety may be an issue in sicker patients, and 
something to look into in future studies.
One safety issue that is concerning is the effect on LDL 
and total cholesterol. Coronary artery disease (CAD) is a 
leading cause of mortality and morbidity in the Western 
world, especially in the US, and a well-known extra-articular 
feature of RA is CAD. This topic may need to be investigated 
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further in those with CAD, a family history of CAD, and/or 
hyperlipidemia. The current recommendation is to check lipid 
levels every six months, but this may need some modification 
in those with established CAD, diabetes mellitus, hyper-
lipidemia, and other comorbidities. Interestingly, IL-6 may 
be a biomarker of carotid artery atherosclerosis,81 and high 
levels of IL-6 have been a predictor of stroke in those with 
atrial fibrillation.82
TCZ has efficacy comparable with other biologics, and 
will be an option for those who fail DMARDs, TNFα inhibi-
tors, and other biologic agents. There are many  therapeutic 
options now, in contrast with a few years ago when clinicians 
only had a choice of three biologics. Before the widespread 
use of these newer biologic medications, clinicians should 
emphasize conventional DMARDs and short courses of 
glucocorticoids when appropriate. The exact time and which 
biologic to initiate is not always clear. Early aggressive 
therapy is recommended, so patients should be followed 
closely because it is not known on presentation who and 
what kind of patient will need treatment escalation. When 
escalation is needed, it could include combination DMARDs 
and/or biologic agents. The use of a second- and third-line 
biologic agent has become a standard after one or more 
has failed.
There are some guidelines put out by various agencies4–6,83 
on RA management but there are still no standard algorithms 
on which biologic to use when there is DMARD failure or 
initial biologic failure. Experience shows that TNF-α inhibi-
tors are used first-line, although there are many choices as 
the “next step” after failure of a TNF-α inhibitor. It will be 
difficult to know which biologic is superior for a patient with 
refractory disease without head-to-head trials comparing the 
different agents. At this point, it looks as though TCZ is a 
promising new agent for those who have failed biologics. 
Future studies will reveal the complete utility of this drug 
along with long-term safety issues. Until then, the use of this 
and other biologics is at the discretion of the provider based 
on each individual’s disease characteristics.
Five-year view
TCZ monotherapy or combination therapy with DMARDs 
can achieve what other biologics have done, ie, improve clini-
cal disease, inhibit radiographic progression, and improve 
quality of life for those with RA. There are many options in 
conventional DMARDs and/or biologics for clinicians in the 
treatment of active RA. Clinical trials comparing biologic 
agents may never be available to help clinicians decide which 
therapy is best for their patients. Most will continue to use 
what they have experience with and only use the newer agents 
for refractory disease unless one of those agents proves to be 
superior to their current practice tendencies.
Predicting which individual will respond to a particular 
DMARD and/or biologic will hopefully be the next forefront 
of therapy in RA. Biomarkers will help us identify which 
patients will respond to a given therapy from their initial pre-
sentation. We hope that one day rheumatologists will be able 
to provide optimal care for RA with a “first-line” agent on a 
case-by-case basis after looking at a biomarker profile.
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